Headed by the successful biotech entrepreneur Grace Yeh, Onward Therapeutics pursues a buy and build strategy with the goal to identify and develop innovative medicines for the treatment of cancer. The company which was founded in 2020 and is based at Biopôle has now closed the first contracts with two biotech start-ups.
Onward Therapeutics acquires licenses for potential development candidates and investing in their partners with platform technologies. The company is led by an experienced team.Grace Yeh, President and CEO of Onward Therapeutics was Founder, President and Chief Executive Officer of PharmaEngine, Inc., a publicly traded commercial stage oncology company headquartered in Taipei, Taiwan with a wholly owned subsidiary in Paris, France. Its market capitalization on the Taipei Exchange exceeded US$1 billion.
(MENAFN - Jordan Times) AMMAN â The Kingdom witnessed a severe drop in temperatures on Wednesday, falling 10 degrees below the annual average, along with persistent gusts of wind, according to ArabiaWeather.
As the depression formed above Cyprus reached the Kingdom on Wednesday morning, temperature in Amman has dropped to 2 degrees Celsius. Meanwhile, heavy snowfall began in Ajloun
Greater Amman Municipality Spokesperson Nasser Rahamneh said that since the onset of extreme weather conditions, the municipality dealt with 65 incidents as of Tuesday evening.
Most of the incidents had resulted from heavy gust of wind reaching more than 100 kilometres per hour, the spokesperson said.
PETROPAVLOVSK. KAZINFORM – Out of 477 schools, 401 with over 31 thousand students are operating as usual in compliance with all the measures of sanitary safety in North Kazakhstan region, the Education Department said, Kazinfrom correspondent reports.
(1)
EMERCell, a biotechnology company developing immunotherapies and cell-based therapies for oncology targets through to pharmaceutical development, announces the signature of a strategic partnership with Onward Therapeutics. The significant investment, of a confidential amount, will be made in three instalments that will allow EMERCell to reach the first human clinical trials. We are delighted to partner with Onward Therapeutics, whose teams have recognized expertise in the development of new drugs in oncology and with whom we have strong synergies. Their participation is a recognition of our expertise and will allow us to accelerate our development, said Patrick Henno, founder and Chairman of EMERCell.